Immuneering plans Phase 2 trial of atebimetinib with chemotherapy in anaplastic thyroid cancer
IMRX•Immuneering plans a potentially registrational Phase 2 trial of atebimetinib with chemotherapy in about 60 patients with anaplastic thyroid cancer, subject to regulatory discussions. It plans to file an investigational new drug application by year-end 2026 and target first dosing for mid-2027.
1. Trial plans
The planned study would enroll about 60 patients whose cancer progressed on standard treatment, including all-comers and a BRAF V600E cohort. Immuneering targets first patient dosing for mid-2027, subject to regulatory clearance, and says topline results could be available 12–18 months after dosing begins. Preclinical findings supporting the combination are scheduled for presentation November 18, 2026, at a symposium in Barcelona.
